An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

Researchers uncover key mechanisms in gene regulation that may lead to better design of RNA-based medicines.

A research team affiliated with UNIST has unveiled an innovative technology to eliminate drug-resistant cancer cells using ...